Latest news with #Tsingke
Yahoo
5 days ago
- Business
- Yahoo
Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities
BEIJING, June 4, 2025 /PRNewswire/ -- Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and peptide therapeutics, held in San Diego from May 19 to 22. As a repeat exhibitor, Tsingke highlighted its integrated "The Great Gene Factory" model, offering precision synthesis solutions from early discovery to large-scale manufacturing. During the exhibition, Tsingke showcased its core offerings including: End-to-End synthesis tools, such as the Syn-HCY Series (12P/192P/768B), delivering high-throughput oligo production for CRISPR, IVD, and research needs GMP production system, featuring the Syn-HL12 synthesizer capable of 200 nmol to 12 mmol scale, equipped with real-time monitoring for UV, pH, and conductivity Application coverage across ASO/siRNA therapeutics, gene editing, mRNA vaccine templates, and diagnostic probes Over 300 chemical modifications and a robust raw material supply chain supporting batch-to-batch consistency Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company's ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners. Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis. For inquiries or collaboration, please contact us at market@ Visit: View original content to download multimedia: SOURCE Tsingke Biotech Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities
BEIJING, June 4, 2025 /PRNewswire/ -- Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and peptide therapeutics, held in San Diego from May 19 to 22. As a repeat exhibitor, Tsingke highlighted its integrated "The Great Gene Factory" model, offering precision synthesis solutions from early discovery to large-scale manufacturing. During the exhibition, Tsingke showcased its core offerings including: End-to-End synthesis tools, such as the Syn-HCY Series (12P/192P/768B), delivering high-throughput oligo production for CRISPR, IVD, and research needs GMP production system, featuring the Syn-HL12 synthesizer capable of 200 nmol to 12 mmol scale, equipped with real-time monitoring for UV, pH, and conductivity Application coverage across ASO/siRNA therapeutics, gene editing, mRNA vaccine templates, and diagnostic probes Over 300 chemical modifications and a robust raw material supply chain supporting batch-to-batch consistency Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company's ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners. Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis. For inquiries or collaboration, please contact us at market@ Visit: View original content to download multimedia: SOURCE Tsingke Biotech Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Tsingke Showcases at AACR 2025 -- Advancing Global Cancer Research with Integrated Synthesis Solutions
BEIJING, May 15, 2025 /PRNewswire/ -- Tsingke Biotech proudly participated in the AACR Annual Meeting 2025, held this April in Chicago, USA. As one of the world's premier events in oncology research, AACR gathered global leaders from academia and industry to explore the future of cancer diagnostics and therapeutics. At Booth #3255, Tsingke presented its comprehensive synthesis and expression service portfolio, offering essential support from early-stage discovery to preclinical development. Our platform drew attention for its capabilities in gene synthesis, oligonucleotide production, mRNA technologies, and protein expression. What Tsingke Offers for Oncology Research High-Throughput Nucleic Acid SynthesisCustom DNA/RNA oligos, siRNA, ASOComplex modifications: LNA, phosphorothioate, dual-labeled probesqPCR and NGS-grade primer/probe production mRNA Synthesis & Raw Materials SupplyIVT template synthesis with 5'/3' modifications and Poly(A) tailsHigh-purity enzymes, capping reagents, modified nucleotides, and buffersReady to support LNP formulation workflows Protein Expression & Antibody ToolsGene synthesis, vector construction, and expression validationFast-turnaround expression services in HEK293/CHO systems Custom R&D Support for Novel TherapiessgRNA libraries, gene editing tools, and RNAi constructs Building a Global Synthesis Engine for Cancer Innovation Tsingke is committed to enabling biotech companies, CDMOs, and academic researchers with a one-stop synthesis platform—from molecular design and synthesis to expression and functional validation. By supporting critical steps in target discovery, validation, and preclinical development, we help accelerate the path from lab to clinic. Interested in learning more or discussing a custom solution?Reach out to us at market@ or visit View original content: SOURCE Tsingke Biotech
